Robert Barrow is the Chief Executive Officer of Definium Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for mitochondrial diseases. With more than 30 years of leadership in the pharmaceutical and biotechnology sectors, Barrow brings unparalleled expertise in drug development, regulatory strategy, and commercialization, particularly for rare and orphan diseases. His career is marked by a proven track record of advancing innovative treatments from discovery through approval, securing substantial funding, and forging strategic partnerships that accelerate patient access to transformative medicines. Prior to Definium, Barrow served as President and CEO of ArmaGen Technologies, where he spearheaded the development of proprietary brain delivery platforms for CNS disorders, culminating in the company's acquisition by Voyager Therapeutics. At PTC Therapeutics, as Executive Vice President and Head of Corporate Development, he was instrumental in the global development and approval of Translarna (ataluren), the first therapy for nonsense mutation Duchenne muscular dystrophy in ambulatory patients in multiple regions. His efforts at PTC expanded the pipeline, raised over $500 million in financing, and established key collaborations with global pharma leaders. At Definium Therapeutics, Barrow leads the charge to address unmet needs in primary mitochondrial myopathies, overseeing the late-stage clinical development of DFD-29, a first-in-class allosteric modulator of mitochondrial complex I. Under his guidance, the company is poised to deliver potentially disease-modifying treatments, building on his history of successfully navigating complex regulatory pathways and driving value creation in biotech.